Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Roche, AbbVie leukemia...

    Roche, AbbVie leukemia drug superior to older medicine in study

    Written by Ruby Khatun Khatun Published On 2017-11-24T09:45:04+05:30  |  Updated On 18 Aug 2021 6:49 AM GMT

    Patients with a type of leukemia that had relapsed who received the new drug Venclexta in combination with Rituxan went significantly longer without the disease worsening than those treated with Rituxan and Treanda, according to interim results from a pivotal late-stage study released on Tuesday.


    Venclexta, sold by Roche and AbbVie, received an accelerated approval to treat chronic lymphocytic leukemia (CLL) patients with a specific genetic mutation who received at least one prior therapy.



    But its continued approval, which was based only on overall response rates seen in an earlier trial, may be contingent on confirmation of clinical benefit.

    The Phase III interim data being presented next month at the American Society of Hematology (ASH) meeting in Atlanta may go a long way to providing that confirmation.



    In the study of 389 patients whose CLL had relapsed after up to three prior treatment regimens, median time until disease worsening, or progression-free survival (PFS), was 17 months for Rituxan plus Treanda, know generically as bendamustine. Median PFS was not yet reached after two years of treatment with the Venclexta combination, including in high-risk patients.

    "The primary analysis of the first Phase III study of Venclexta in relapsed/refractory CLL shows a profound improvement in PFS versus standard bendamustine/Rituxan, with consistent effects in all-risk subsets," researchers concluded in a brief summary of interim data released on Tuesday.


    The overall response rate was 93.3 percent for Venclexta plus Rituxan versus 67.7 percent who responded to Treanda/Rituxan.


    A complete response, meaning no detectable sign of cancer-based on bone marrow assessment and CT scan, was observed in 26.8 percent of those who received Venclexta (venetoclax) plus Rituxan versus 8.2 percent of those in the control group.


    The results were deemed to be highly statistically significant.


    Adverse reactions leading to deaths were reported in 10 Venclexta patients (5.2 percent) and 11 in the Treanda group (5.9 percent).

    https://pubads.g.doubleclick.net/gampad/ads?iu=/21687779244/clinicalkey_video_ad&description_url=[placeholder]&tfcd=0&npa=0&sz=640x480&gdfp_req=1&output=vast&unviewed_position_start=1&env=vp&impl=s&correlator=

    CLL is a slowly progressing blood cancer that primarily affects older adults. About 20,000 new cases of CLL are diagnosed in the United States each year, according to the American Cancer Society.


    Treanda is sold by Teva Pharmaceutical Industries and Rituxan (rituximab) is sold by Roche and Biogen.




    (Reporting by Bill Berkrot; Editing by James Dalgleish)



    AbbVie bendamustine Chronic lymphocytic leukemia leukemia leukemia drug medicine pharma news Rituxan Roche superior Treanda Venclexta 
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      X